Alnylam has restructured their development agreement with Sanofi Genzyme for fitusiran. Under the new agreement, Sanofi Genzyme will take over all development activities and conduct of the clinical studies. Sanofi will have global commercialization rights. This is the next step in Sanofi becoming a major hemophilia treatment organization. They recently also obtained FDA approval of Hemlibra, an innovative treatment for hemophilia A.